Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Insurers, doctors battle over new heart disease drugs
CNBC
Fri, 09/8/17 - 09:30 am
Tags:
insurers, cardiovascular disease, statins, PCSK9 inhibitors, Amgen, Regeneron, Sanofi, Repatha, Praluent
3 Strong Biotech Stocks In 2017
Forbes
Mon, 09/4/17 - 10:35 pm
Tags:
Regeneron, Calithera Biosciences, Dynavax Technologies
In cost debate, Amgen stands by Repatha's value
BioPharma Dive
Wed, 08/23/17 - 11:36 am
Tags:
Amgen, Repatha, drug pricing, PCSK9 inhibitors, Praluent, Sanofi, Regeneron
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Fierce Pharma
Wed, 08/23/17 - 11:21 am
Tags:
Pfizer, Eucrisa, DTC, eczema, Dupixent, Sanofi, Regeneron
In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure
Endpoints
Mon, 08/14/17 - 09:36 pm
Tags:
Regeneron, RSV, clinical trials, REGN2222, suptavumab
Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance
Endpoints
Thu, 08/3/17 - 11:19 am
Tags:
Sanofi, R&D, Regeneron, drug development
Regeneron Earnings, Revenue Top Views; Shares Down Slightly
Investors Business Daily
Thu, 08/3/17 - 11:12 am
Tags:
Regeneron, earnings
Earnings Preview: What To Expect From Regeneron Pharmaceuticals on Thursday
Forbes
Wed, 08/2/17 - 09:37 am
Tags:
Regeneron, earnings
Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent
Fierce Pharma
Sun, 07/16/17 - 02:53 pm
Tags:
payers, Sanofi, Regeneron, eczema, Dupixent, dupilumab
The top 15 highest-paid biopharma executives
Fierce Pharma
Fri, 07/14/17 - 08:42 am
Tags:
executive pay, Mylan Labs, Valeant Pharmaceuticals, Medivation, Regeneron, JNJ, Merck
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
Tue, 06/27/17 - 09:45 am
Tags:
AbbVie, biosimilars, Humira, Clovis Oncology, Rubraca, Novartis, Regeneron, Eylea
Novartis trial results could spell trouble for Regeneron
Drug Delivery Business News
Wed, 06/21/17 - 07:33 pm
Tags:
Novartis, Regeneron, clinical trials, RTH258, neovascular age-related macular degeneration
Regeneron’s Praluent May See Gradual Increase in 2017 Demand
Market Realist
Tue, 06/20/17 - 09:31 am
Tags:
Regeneron, Praluent, Sanofi
Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron
Endpoints
Tue, 06/20/17 - 08:51 am
Tags:
Novartis, Eylea, Regeneron, RTH258
Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics
Fierce Pharma
Mon, 06/12/17 - 09:42 am
Tags:
Sanofi, Regeneron, Praluent, diabetes, LDL cholesterol
Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick
Motley Fool
Mon, 06/5/17 - 10:09 am
Tags:
Regeneron
Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price
Fierce Pharma
Wed, 05/24/17 - 10:35 am
Tags:
Sanofi, Regeneron, Kevzara, rheumatoid arthritis
Celgene, Regeneron and Vertex execs, NIH chief head to White House as threat of Trump funding cuts looms
Fierce Biotech
Mon, 05/8/17 - 10:04 pm
Tags:
biotech, Celgene, Regeneron, Vertex Pharmaceuticals, NIH, Donald Trump
Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts
Fierce Pharma
Mon, 05/8/17 - 11:38 am
Tags:
Sanofi, Regeneron, drug launches, Dupixent, eczema
Regeneron posts mixed Q1 results, Eylea growth slows
Drug Delivery Business News
Sun, 05/7/17 - 10:13 am
Tags:
Regeneron, earnings, Eylea

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.